Cytokinetics Inc
NASDAQ:CYTK
Cytokinetics Inc
NASDAQ:CYTK
Price:
65.28 USD
0.35%
Market Closed
Updated:
May 8, 2024
Section:
Relative Value
The Relative Value of one
CYTK
stock under the Base Case scenario is
40.64
USD.
Compared to the current market price of 65.28 USD,
Cytokinetics Inc
is
Overvalued by 38%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CYTK
Relative Value
Base Case
40.64
USD
Overvaluation 38%
Valuation Multiples
Multiples Across Competitors
CYTK Competitors Multiples
Cytokinetics Inc Competitors
Cytokinetics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cytokinetics Inc
NASDAQ:CYTK
|
6.6B USD | 881.1 | -12.6 | -12.6 | -12.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
282.8B USD | 5.2 | 58.7 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
163.1B USD | 5.5 | 43.4 | 18.4 | 30.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.8B USD | 11 | 30 | 24.2 | 25.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.5B USD | 8.1 | 27.3 | 22.1 | 24.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81B USD | 3 | 167.4 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.5B USD | 9 | -7.8 | -8.5 | -7.5 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 3.3 | 27.5 | 14.1 | 17.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.3 | 46 | 63.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
